| [1] Taylor AM, Hsueh MF, Ranganath LR, et al. Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing. Rheumatology (Oxford). 2017. DoI: 10.1093/rheumatology/kew355.[2] Goldring SR. Alterations in periarticular bone and cross talk between subchondral bone and articular cartilage in osteoarthritis. Ther Adv Musculoskelet Dis. 2012;4(4):249-258.[3] Barreto G, Soininen A, Ylinen P, et al. Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis. Arthritis Res Ther. 2015;17:379.[4] Cornejo MC, Cho SK, Giannarelli C, et al. Soluble factors from the notochordal-rich intervertebral disc inhibit endothelial cell invasion and vessel formation in the presence and absence of pro-inflammatory cytokines. Osteoarthritis Cartilage. 2015;23(3):487-496.[5] Ramme AJ, Lendhey M, Raya JG, et al. A novel rat model for subchondral microdamage in acute knee injury: a potential mechanism in post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2016;24(10):1776-1785.[6] Henrotin Y, Pesesse L, Sanchez C. Subchondral bone and osteoarthritis: biological and cellular aspects. Osteoporos Int. 2012;23 Suppl 8:S847-S851.[7] Novak T, Fites GK, Xu X, et al. In Vivo Cellular Infiltration and Remodeling in a Decellularized Ovine Osteochondral Allograft. Tissue Eng Part A. 2016;22(21-22):1274-1285.[8] Filip A, Pinzano A, Bianchi A, et al. Expression of the semicarbazide-sensitive amine oxidase in articular cartilage: its role in terminal differentiation of chondrocytes in rat and human. Osteoarthritis Cartilage. 2016;24(7):1223-1234.[9] Dore DA, Winzenberg TM, Ding C, et al. The association between objectively measured physical activity and knee structural change using MRI. Ann Rheum Dis. 2013;72(7): 1170-1175.[10] Madden RM, Han SK, Herzog W. The effect of compressive loading magnitude on in situ chondrocyte calcium signaling. Biomech Model Mechanobiol. 2015;14(1):135-142.[11] Pritchard JM, Papaioannou A, Tomowich C, et al. Bone mineralization is elevated and less heterogeneous in adults with type 2 diabetes and osteoarthritis compared to controls with osteoarthritis alone. Bone. 2013;54(1):76-82.[12] Chen Y, Wang T, Guan M, et al. Bone turnover and articular cartilage differences localized to subchondral cysts in knees with advanced osteoarthritis. Osteoarthritis Cartilage. 2015; 23(12):2174-2183.[13] Steinbeck MJ, Eisenhauer PT, Maltenfort MG, et al. Identifying Patient-Specific Pathology in Osteoarthritis Development Based on MicroCT Analysis of Subchondral Trabecular Bone. J Arthroplasty. 2016;31(1):269-277.[14] Sergijenko A, Roelofs AJ, Riemen AH, et al. Bone marrow contribution to synovial hyperplasia following joint surface injury. Arthritis Res Ther. 2016;18:166.[15] Muratovic D, Cicuttini F, Wluka A, et al. Bone marrow lesions detected by specific combination of MRI sequences are associated with severity of osteochondral degeneration. Arthritis Res Ther. 2016;18:54.[16] Moon HJ, Yurube T, Lozito TP, et al. Effects of secreted factors in culture medium of annulus fibrosus cells on microvascular endothelial cells: elucidating the possible pathomechanisms of matrix degradation and nerve in-growth in disc degeneration. Osteoarthritis Cartilage. 2014;22(2):344-354.[17] Saito M, Sasho T, Yamaguchi S, et al. Angiogenic activity of subchondral bone during the progression of osteoarthritis in a rabbit anterior cruciate ligament transection model. Osteoarthritis Cartilage. 2012;20(12):1574-1582.[18] Wang B, Zhou X, Price C, et al. Quantifying load-induced solute transport and solute-matrix interaction within the osteocyte lacunar-canalicular system. J Bone Miner Res. 2013;28(5): 1075-1086.[19] Shabestari M, Vik J, Reseland JE, et al. Bone marrow lesions in hip osteoarthritis are characterized by increased bone turnover and enhanced angiogenesis. Osteoarthritis Cartilage. 2016; 24(10):1745-1752.[20] Tanaka Y. Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33 (4 Suppl 92):S58-S62.[21] Gabay O, Zaal K J, Sanchez C, et al. Sirt1-deficient mice exhibit an altered cartilage phenotype. Joint Bone Spine. 2013; 80(6):613-620.[22] Leyh M, Seitz A, Durselen L, et al. Subchondral bone influences chondrogenic differentiation and collagen production of human bone marrow-derived mesenchymal stem cells and articular chondrocytes. Arthritis Res Ther. 2014;16(5):453.[23] Das RH, Jahr H, Verhaar JA, et al. In vitro expansion affects the response of chondrocytes to mechanical stimulation. Osteoarthritis Cartilage. 2008;16(3):385-391.[24] Khattab HM, Aoyama E, Kubota S, et al. Physical interaction of CCN2 with diverse growth factors involved in chondrocyte differentiation during endochondral ossification. J Cell Commun Signal. 2015;9(3):247-254.[25] Hayashi J, Kihara M, Kato H, et al. A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis. Clin Proteomics. 2015;12(1):20.[26] Prasadam I, Farnaghi S, Feng J Q, et al. Impact of extracellular matrix derived from osteoarthritis subchondral bone osteoblasts on osteocytes: role of integrinbeta1 and focal adhesion kinase signaling cues. Arthritis Res Ther. 2013;15(5):R150.[27] Sharma AR, Jagga S, Lee SS, et al. Interplay between cartilage and subchondral bone contributing to pathogenesis of osteoarthritis. Int J Mol Sci. 2013;14(10):19805-19830.[28] Bolon B, Grisanti M, Villasenor K, et al. Generalized Degenerative Joint Disease in Osteoprotegerin (Opg) Null Mutant Mice. Vet Pathol. 2015;52(5):873-882.[29] Chen S, Huang Y, Chen W, et al. Protective effects of the Tougu Xiaotong capsule on morphology and osteoprotegerin/nuclear factor-kappaB ligand expression in rabbits with knee osteoarthritis. Mol Med Rep. 2016;13(1): 419-425.[30] Bellido M, Lugo L, Roman-Blas JA, et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage. 2011;19(10): 1228-1236.[31] Zeng JZ, Wang ZZ, Ma LF, et al. Increased receptor activator of nuclear factor kappabeta ligand/osteoprotegerin ratio exacerbates cartilage destruction in osteoarthritis in vitro. Exp Ther Med. 2016;12(4):2778-2782.[32] Sagar DR, Ashraf S, Xu L, et al. Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis. Ann Rheum Dis. 2014;73(8):1558-1565.[33] Abed E, Bouvard B, Martineau X, et al. Elevated hepatocyte growth factor levels in osteoarthritis osteoblasts contribute to their altered response to bone morphogenetic protein-2 and reduced mineralization capacity. Bone. 2015;75:111-119.[34] Shibasaki S, Tsunemi S, Kitano S, et al. Differential regulation of c-Met signaling pathways for synovial cell function. Springerplus. 2014;3:554.[35] Oh H, Kwak JS, Yang S, et al. Reciprocal regulation by hypoxia-inducible factor-2alpha and the NAMPT-NAD(+)-SIRT axis in articular chondrocytes is involved in osteoarthritis. Osteoarthritis Cartilage. 2015; 23(12):2288-2296.[36] Bae WJ, Shin MR, Kang SK, et al. HIF-2 Inhibition Supresses Inflammatory Responses and Osteoclastic Differentiation in Human Periodontal Ligament Cells. J Cell Biochem. 2015; 116(7):1241-1255.[37] Lin N Y, Distler A, Beyer C, et al. Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Ann Rheum Dis. 2016;75(11):2037-2044.[38] Ryu J H, Shin Y, Huh Y H, et al. Hypoxia-inducible factor-2alpha regulates Fas-mediated chondrocyte apoptosis during osteoarthritic cartilage destruction. Cell Death Differ. 2012;19(3):440-450.[39] Saito T, Fukai A, Mabuchi A, et al. Transcriptional regulation of endochondral ossification by HIF-2 alpha during skeletal growth and osteoarthritis development. Nat Med. 2010; 16(6):678-686.[40] Ishizuka S, Sakai T, Hiraiwa H, et al. Hypoxia-inducible factor-2alpha induces expression of type X collagen and matrix metalloproteinases 13 in osteoarthritic meniscal cells. Inflamm Res. 2016;65(6):439-448.[41] Markway BD, Cho H, Zilberman-Rudenko J, et al. Hypoxia-inducible factor 3-alpha expression is associated with the stable chondrocyte phenotype. J Orthop Res. 2015;33(11):1561-1570.[42] van der Kraan PM, Blaney DE, van den Berg WB. A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis. Arthritis Res Ther. 2010;12(1):201.[43] Zhen G, Wen C, Jia X, et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704-712.[44] Lu C, Wan Y, Cao J, et al. Wnt-mediated reciprocal regulation between cartilage and bone development during endochondral ossification. Bone. 2013;53(2):566-574.[45] Kuchler U, Schwarze U Y, Dobsak T, et al. Dental and periodontal phenotype in sclerostin knockout mice. Int J Oral Sci. 2014;6(2):70-76.[46] Weng LH, Wang CJ, Ko J Y, et al. Control of Dkk-1 ameliorates chondrocyte apoptosis, cartilage destruction, and subchondral bone deterioration in osteoarthritic knees. Arthritis Rheum. 2010;62(5):1393-1402.[47] Inkson CA, Ono M, Kuznetsov S A, et al. TGF-beta1 and WISP-1/CCN-4 can regulate each other's activity to cooperatively control osteoblast function. J Cell Biochem. 2008;104(5):1865-1878.[48] Walsh DA, Mcwilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford). 2010;49(10):1852-1861.[49] Nagai T, Sato M, Kutsuna T, et al. Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair. Arthritis Res Ther. 2010;12(5):R178.[50] Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521-1531.[51] Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2014;73(9): 1665-1672.[52] Brown MT, Murphy FT, Radin DM, et al. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum. 2013; 65(7):1795-1803.[53] Spierings EL, Fidelholtz J, Wolfram G, et al. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013; 154(9):1603-1612.[54] 王呈,薄其玉,戴国锋,等.小分子药物Kartogenin诱导骨髓间充质干细胞定向分化中基质金属蛋白酶2的表达[J].中国组织工程研究,2016,20(50):7475-7480. |
.jpg)
.jpg)